Overcoming Chemotherapy Resistance in SCLC

被引：64
|
作者：
Herzog, Brett H. [1 ,2 ]
Devarakonda, Siddhartha [1 ,2 ]
Govindan, Ramaswamy [1 ,2 ]
机构：
[1] Washington Univ, Dept Med, Div Oncol, Sch Med, St Louis, MO USA
[2] Washington Univ, Alvin J Siteman Canc Ctr, St Louis, MO USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 12期
基金：
美国国家卫生研究院;
关键词：
Small cell lung cancer; SCLC; Chemotherapy; Resistance; Chemoresistance; CELL LUNG-CANCER; GENE-EXPRESSION; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; PROMOTES CHEMORESISTANCE; THERAPEUTIC TARGETS; LSD1; INHIBITORS; P-GLYCOPROTEIN; GROWTH; TWIST1;
D O I：
10.1016/j.jtho.2021.07.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SCLC is an aggressive form of lung cancer with a very poor prognosis. Although SCLC initially responds very well to platinum-based chemotherapy, it eventually recurs and at recurrence is nearly universally resistant to therapy. In light of the recent advances in understanding regarding the biology of SCLC, we review findings related to SCLC chemotherapy resistance. We discuss the potential clinical implications of recent preclinical discoveries in altered signaling pathways, transcriptional landscapes, metabolic vulnerabilities, and the tumor microenvironment. (c) 2021 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.
引用
收藏
页码：2002 / 2015
页数：14
相关论文
共 50 条
  • [31] Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC)
    Yeseul Kim
    Elena Vagia
    Pedro Viveiros
    Cyra Y. Kang
    Ju Young Lee
    Gahyun Gim
    Sukjoo Cho
    Horyun Choi
    Leeseul Kim
    Inae Park
    Jaeyoun Choi
    Young Kwang Chae
    Cancer Immunology, Immunotherapy, 2021, 70 : 961 - 965
  • [32] Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC)
    Kim, Yeseul
    Vagia, Elena
    Viveiros, Pedro
    Kang, Cyra Y.
    Lee, Ju Young
    Gim, Gahyun
    Cho, Sukjoo
    Choi, Horyun
    Kim, Leeseul
    Park, Inae
    Choi, Jaeyoun
    Chae, Young Kwang
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (04) : 961 - 965
  • [33] CHEMOTHERAPY Continued lack of progress in SCLC
    Subramanian, Janakiraman
    Govindan, Ramaswamy
    NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (02) : 77 - 78
  • [34] A comparison of ACE and CE chemotherapy in SCLC
    Bakerley, ND
    Keaney, NP
    Sridharan, K
    Taylor, IK
    Clague, HW
    THORAX, 2002, 57
  • [35] An audit of SCLC patients not receiving chemotherapy
    Morris, J.
    Woolnough, K.
    Sheldon, J.
    Nanda, U.
    Beckett, P.
    LUNG CANCER, 2009, 63 : S10 - S10
  • [36] Second line chemotherapy for recurrent SCLC: The West of Scotland SCLC retrospective database
    Slater, S.
    McKay, S.
    MacLaren, V.
    Hicks, J.
    LUNG CANCER, 2014, 83 : S64 - S65
  • [37] Overcoming multidrug resistance by a combination of chemotherapy and photothermal therapy mediated by carbon nanohorns
    Wang, Junling
    Wang, Ran
    Zhang, Fangrong
    Yin, Yajun
    Mei, Leixia
    Song, Fengjuan
    Tao, Mingtao
    Yue, Wanqing
    Zhong, Wenying
    JOURNAL OF MATERIALS CHEMISTRY B, 2016, 4 (36) : 6043 - 6051
  • [38] Overcoming Chemotherapy Resistance: A Nanomedicine Approach to Triple-Negative Breast Cancer
    Liu, Xueying
    Kinoh, Hiroaki
    Quader, Sabina
    Cabral, Horacio
    Kataoka, Kazunori
    CANCER SCIENCE, 2025, 116 : 1234 - 1234
  • [39] An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy
    Takara, K
    Sakaeda, T
    Okumura, K
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (03) : 273 - 286
  • [40] Overcoming the chemotherapy resistance in non-small-cell lung cancer by tamoxifen
    Bogush, Tatiana
    Dudko, Evgeniy
    Bogush, Elena
    Tikchomirov, Mikchail
    Beme, Anna
    Laktionov, Konstantin
    Vakhtadze, Levan
    Polotsky, Boris
    Davydov, Mikchail
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S634 - S635
12345